Agios Pharmaceuticals AGIO Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
December 31, 2025 was $572.7 million and $136.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of June 30, 2026 and December 31, 2025. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of June 30, 2026 and December 31, 2025.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Agios Pharmaceuticals (AGIO) reported cash, cash equivalents, and marketable securities of $572.7M in Q2 2026.
- How has Agios Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- Agios Pharmaceuticals's cash, cash equivalents, and marketable securities decreased by 8.6% year-over-year, from $626.8M to $572.7M.
- What is the long-term trend for Agios Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's cash, cash equivalents, and marketable securities has grown at a -14.6% compound annual growth rate (CAGR), from $299M to $136.2M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Agios Pharmaceuticals's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
